Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Conference News ACC 2015

Anticoagulation With Off-Switch Fails to Improve PCI Outcomes, Sparks Allergic Reactions

Todd Neale

March 15, 2015

Advertisement

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

What’s Going to Be Hot at ACC 2025?

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Anticoagulation With Off-Switch Fails to Improve PCI Outcomes, Sparks Allergic Reactions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content